Medcolcanna Announces Extension of Filing Deadline of its Interim Financial Statements and MD&A
August 21 2020 - 4:15PM
Medcolcanna Organics Inc. (TSX-V: MCCN)
(“
Medcolcanna” or the “
Company”),
a Canadian medical cannabis company with operations in Colombia,
announces that due to the COVID-19 pandemic, the Company intends to
postpone the filing of its unaudited interim consolidated financial
statements and accompanying management's discussion and analysis
and related CEO and CFO certifications for the period ended June
30, 2020 (collectively, the "
Interim Filings"),
which are required to be filed by August 29, 2020, under Sections
4.4 and 5.1(2) of National Instrument 51-102 - Continuous
Disclosure Obligations.
On May 19, 2020, the Canadian Securities
Administrators (CSA) announced that they would provide issuers with
a 45-day filing extension for filings required from June 2 to
August 31, 2020, to allow issuers the time needed to focus on the
many other business and financial reporting implications of the
COVID-19 pandemic.
The Company will rely on this exemption with
respect to the Interim Filings in accordance with BC Instrument
51-517 - Temporary Exemption from Certain Corporate Finance
Requirements with Deadlines during the Period from June 2 to August
31, 2020. The Company is continuing to work diligently and
expeditiously to file the Interim Filings and currently expects
them to be filed on or prior to the extended filing deadline of
October 13, 2020.
Until such time as the Interim Filings are
filed, management and other insiders of Medcolcanna are subject to
a trading black-out that reflects the principles in section 9 of
National Policy 11-207.
The Company confirms there have been no
undisclosed material business developments since June 1, 2020, the
date of filing the Company's 2019 year end and first-quarter
interim financial statements for the period ended March 31, 2020,
except as otherwise disclosed in this press release or previous
press releases since that date.
ABOUT MEDCOLCANNA
Medcolcanna is a Canadian integrated medical
cannabis company, whose fully licensed operations are based in
Colombia. Led by a proven and successful management team,
Medcolcanna has facilities in optimal growing locations which
positions the Company to become a global leader in the medical
cannabis market.
Medcolcanna employs state of the art organic
agricultural technology and innovative pharmaceutical processes to
produce high-quality products. The Company’s scalable production
model and network of pharmaceutical partnerships globally ensures
that they remain at the forefront of the medical cannabis
industry.
If you would like to receive News Releases via
e-mail as soon as they are published, please subscribe here:
https://medcolcanna.com/contact-us/
Additional information about Medcolcanna can be
found on its web site at www.medcolcanna.com
Neither the TSX Venture Exchange Inc. nor
its regulation services provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this
release.
Investor Relations
Contact:Chris Reid, CFOCarrera 49b # 93-62Bogotá,
ColombiaEmail: info@medcolcanna.com
Felipe de la Vega, CEOCarrera 49b # 93-62Bogotá,
ColombiaEmail: info@medcolcanna.com
Forward-Looking Statements
This news release contains “forward-looking
information” and “forward-looking statements” (collectively,
“forward-looking statements”) within the meaning
of the applicable Canadian securities legislation. All statements,
other than statements of historical fact, are forward-looking
statements and are based on expectations, estimates and
projections as at the date of this news release. Any
statement that involves discussions with respect to predictions,
expectations, beliefs, plans, projections, objectives, assumptions,
future events or performance (often but not always using phrases
such as “expects”, or “does not expect”, “is expected”,
“anticipates” or “does not anticipate”, “plans”, “budget”,
“scheduled”, “forecasts”, “estimates”, “believes” or “intends” or
variations of such words and phrases or stating that certain
actions, events or results “may” or “could”, “would”, “might” or
“will” be taken to occur or be achieved) are not statements of
historical fact and may be forward-looking statements.
Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable, are
subject to known and unknown risks, uncertainties, and
other factors which may cause the actual results
and future events to differ materially from those
expressed or implied by such forward-looking statements. Such
factors include, but are not limited to general business, economic,
competitive, political and social uncertainties; and the delay or
failure to receive board, shareholder or
regulatory approvals. There can be no assurance that such
statements will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on
the forward-looking statements and information contained in this
news release.
Medcolcanna assumes no obligation to update the
forward-looking statements of beliefs, opinions, projections, or
other factors, should they change, except as required by law.
Medcolcanna Organics (TSXV:MCCN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Medcolcanna Organics (TSXV:MCCN)
Historical Stock Chart
From Dec 2023 to Dec 2024